Table 4 Clinical data for ankylosing spondylitis patients in stratified by fecal calprotectin positivity
From: Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study
|  | Fecal calprotectin cutoff 50 μg/g | ||
|---|---|---|---|
| Â | Fecal calprotectin positive (n= 16) | Fecal calprotectin negative (n= 23) | Pvalue |
NSAID use | 6 (38%) | 10 (43%) | 0.75 |
Enbrel use | 9 (56%) | 8 (35%) | 0.20 |
Patients waking up at night for bowel movement | 3 (19%) | 3 (13%) | 0.67 |
BASDAI score | 3.0 (0.1 to 7.75) | 1.8 (0.03 to 7.66) | 0.16 |
BASRI score | 6.0 (2 to 13.5) | 5.0 (2 to 11) | 0.64 |
BASFI score | 41.6 (0.4 to 92.5) | 17.1 (0 to 72.1) | 0.09 |
Erythrocyte sedimentation rate | 8.5 (0 to 62) | 17 (2 to 64) | 0.75 |
C-reactive protein | 0.44 (0.03 to 5.7) | 0.57 (0.02 to 4.84) | 0.58 |
Patients with history of uveitis | 7 (44%) | 10 (43%) | 1.0 |
Patients with history of peripheral arthritis in the knee | 4 (25%) | 5 (22%) | 1.0 |
Patients with history of peripheral arthritis in the ankle | 5 (31%) | 4 (17%) | 0.44 |